

Special Issue

Tumor Microenvironment Targeted and Immunotherapies for Brain Cancer

Message from the Guest Editor

Primary and metastatic brain cancers still represent an unmet clinical need with an urgent need for improved therapy options. The emerging field of neuro-immunology provides unprecedented opportunities for the development of novel therapeutic avenues that target different immune cell types, aiming at improving immune recognition and destruction of cancer cells or the blockade of tumor-promoting functions of cells of the tumor immune microenvironment in primary and metastatic cancers. This Special Issue will focus on recent developments in tumor microenvironment-targeted therapies and immunotherapies for primary and metastatic brain cancers and welcomes original articles or reviews highlighting novel therapeutic strategies of inducing anti-cancer immune responses or blocking tumor-promoting functions of brain-resident or recruited immune cell types in CNS tumors.

Guest Editor

Dr. Lisa Sevenich

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/101777

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)